Amylyx Pharmaceuticals Inc. (AMLX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Amylyx Pharmaceuticals In... (AMLX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.14

-0.04 (-1.26%)

At close: Jan 14, 2025, 3:59 PM

3.12

-0.64%

Pre-market Jan 15, 2025, 05:13 AM EST

undefined% (undefined)

Bid	3.15
Market Cap	215.24M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.82
PE Ratio (ttm)	-0.82
Forward PE	n/a
Analyst	Hold

Ask	3.4
Volume	1,064,161
Avg. Volume (20D)	1,260,086
Open	3.10
Previous Close	3.18
Day's Range	3.02 - 3.23
52-Week Range	1.57 - 19.95
Beta	undefined

About AMLX

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 7, 2022

Employees 384

Stock Exchange NASDAQ

Ticker Symbol AMLX

Website https://amylyx.com

Analyst Forecast

According to 7 analyst ratings, the average rating for AMLX stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 154.78% from the latest price.

Buy 42.86%

Hold 57.14%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

+11.34%

Amylyx Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

6 months ago · Source

+25.45%

Amylyx Pharmaceuticals shares are trading higher after the company announced that it acquired avexitide from Eiger BioPharmaceuticals.

News

5 days ago · businesswire.com

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 shares of its co...

6 days ago · businesswire.com

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common...

1 week ago · businesswire.com

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer.

1 month ago · businesswire.com

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexi...

1 month ago · businesswire.com

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference.

1 month ago · seekingalpha.com

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 O...

2 months ago · seekingalpha.com

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee ...

2 months ago · fool.com

Why Amylyx Pharmaceuticals Stock Was So Healthy This Week

The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.

3 months ago · businesswire.com

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024.